Aura Biosciences Inc.

Ocular Oncology

Aura Biosciences Inc. focuses on clinical research in primary indeterminate lesions and small choroidal melanoma, with an emphasis on conditions affecting the eye and surrounding tissues.

  • Choroidal melanoma
  • Indeterminate ocular lesions
  • Eye cancer

The sponsor’s research activity is centered on therapeutic options for localized ocular malignancy and lesion management within ophthalmic oncology.

Retinal and Choroidal Disorders

Its clinical portfolio includes disorders involving the choroid and adjacent ocular structures, with attention to preserving vision in patients with small malignant or suspicious lesions.

  • Choroidal tissue
  • Ocular lesion treatment
  • Vision-preserving therapies

Research activity in this area aligns with the treatment of localized disease in anatomically sensitive parts of the eye.

Targeted Local Therapy

The sponsor is engaged in research on targeted ophthalmic therapy for lesions confined to the eye, reflecting interest in treatments designed for localized disease control.

  • Localized treatment
  • Ocular tumor control
  • Sham-controlled evaluation

This area highlights therapeutic development for precise intervention in small eye tumors and related lesions.

Visual Health and Preservation

Clinical work supported by the sponsor is relevant to maintaining visual function while addressing ocular neoplasms and suspicious pigmented lesions.

  • Visual preservation
  • Ocular neoplasm management
  • Eye-sparing treatment

The therapeutic focus is concentrated on eye-directed interventions for patients with early-stage or limited ocular disease.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on the Effectiveness and Safety of Belzupacap Sarotalocan for Patients with Small Choroidal Melanoma or Indeterminate Lesions

    Not recruiting

    1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +6